● Recruiting

A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)

Condition: Biliary Tract Cancer · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

PhasePhase 3

Planned participants538

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 compared with the investigator's choice of protocol in patients with locally advanced or metastatic biliary tract cancer who have failed prior platinum-based chemotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Sa Xiao, PHD · 15013238943 · xiaosa@baili-pharm.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07582315